In this concise section of TRASCI What's Happening I am pleased to offer readers five mini-reports reflecting on mass production of transfusable human cultured cells destined for substitution therapy. Special thanks are due to my contributors for helping me to bring together this concise theme which highlights supportive studies for implementation of culturing blood cells with a focus on advances in cultured RBC \[CRBC\]. Also, I am, in particular, grateful to Prof. Jason Acker for reviewing my personal contributions to this theme. Readers will note how few, if any large-scale, high-quality randomized trials actually exist in this area. In the absence of newly published scientific data and a lack of response by many investigators who I am aware are working on this topic, I had no option but to introduce a personal reflection. I have invited some close friends to join me in this venture, with the hope that, together, this theme will be of interest and have educational value to those investigators who wish to be involved in the research development and clinical use of cultured bioproducts. For those sufficiently familiar with the development of *in vitro* cultured blood cells, some consideration of the potential harm that cultured bioproducts might bring is highlightedin this section. Where required, further in-depth studies on the quality/ safety and functionality aspects of the cultured cells, in particular using modern technologies that detect the subtle shape and size changes and red cell microvesiculation profiles, are explored in some detail.

From an operational point of view, we are capable of producing limited quantities of all type of cultured cells *in vitro*. For example, more than 10^8^ hepatocytes / organoid unit can be produced, which is an equivalent number of cells required for human transplant applications. The number of hepatocytes used in transplantation trials for a standard therapeutic scale is \> 10^9^ hepatocytes per patient.

The main objective of this theme on cultured cells is, therefore, to bring together international colleagues to reflect jointly on where we are at with the mass-production of highly standardized, reproducible blood cells for transfusion therapy. We begin, first, with an exploration of several rousing questions of both a qualitative and quantitative nature, which lead to additional medical- and moral- ethical questions in "What is fact and what is fiction?" by Prof. Cees Smith Sibinga. Then, we explore the methodological aspects of *in vitro* culture, where Dr. Jean Amiral and I discuss production of all cultured blood cells and include a discussion on organoids for the sake of completeness of the cultured cell topics. These interesting commentary items on the implementation of cultured technologies is supported by a personal review of advances made in the production of cultured red blood cells that are now achievable through the perseverance and the contributions of multiple academic and industrial collaborations and with the use of clinical-grade components. The availability of genetically characterized stem cells, defined media and substrates, and microwell plates, which permit microscopic verification of preparations have positioned this work for future clinical trials. This concise mini -report focuses on the operational aspects of cultured red blood cell production, and provides a fresh look at the secret lives of the highly standardised, "one product' type for all concept" that may be achievable with CRBCs.

Conceptually, to achieve the best strategic policies and practices to support the *in vitro* culture of blood cells in the most effective and economical way, four major issues need to be addressed: 1. Selection of the best starting cell lines as they contribute to the rate of expansion and the characteristics of the final product; 2) Long-term stability of the expansion media, as evidence is accumulating that lack of stability can lead to the waste of effort and time; and 3. Immortalization of the source materials and; 4) establishment of the most appropriate quality indicators that are relevant to *in vivo* function and to set minimum standards for what is critical to quality. While all of these factors are highly complex and challenging, the issue of the immortalization of cell line sources requires special consideration as the progenitor genome can be slightly modified to immortalize the cell line. Ensuring that the derived mature erythrocytes do not carry any mutagenesis risk for related patients is critical. While there is not enough long term data to truly understand this risk, the potential for possible malignancies in patients warrants caution as efforts are undertaken to immortalize the source materials.

On reflection, there is little doubt that various human derived stem cells, of differing origins, can be used to produce functionally viable cultured red blood cells that functionally replicate conventional blood cells. The use of robust and standardised manufacturing processes which are compliant with strict GMP regulations can not only provide large amounts of the desired bioproducts for clinical use, but bring about the benefit of avoiding the ever unresolved problems of donor dependency. An additional bonus is that cultured cells may be less immunogenic and possibly being compositionally and functionally consistent than conventional donor-derived products.

In our third paper, Dr. Olivier Garraud, the TRASCI Clinical Trials Section Editor, undertakes a SWOT analysis on the methodological considerations surrounding the production of cultured red cells and platelet concentrates. He emphasizes, in his report, that the core whole blood-derived conventional blood components require additional processing including component separation, leukoreduction and pathogen inactivation to enhance their safety profile. These processes can affect the quality, quantity, overall transfusion cost and clinical efficacy. In this context it is important that parameters that have an impact on the quality and safety of storage blood components, such as release of microvesicles and biological response modifiers need to be fully investigated in view of their potential long-term immunomodulatory impact on recipients.

Finally, I have included a summary of work in progress by a Spanish group to produce platelets from megakaryocytes. This group focused on how to provide a reliable and highly efficient production method for the culture of viable and functional platelets for transfusion. Little is known on how long cultured platelet products can be stored, or whether any additional safety measures should be implemented (*i.e. filtration or* pathogen reduction technologies). There is no consensus on the quality assessment of cultured platelets as the conditions for culture and viability assessment are still under development. It is acknowledged that differences in platelet function are dependent on the source material used and the methods of manufacturing. As the characteristics of cultured platelets may need to consider the needs of the transfusion recipient, it is important to highlight that platelet function is more diverse than originally thought. Current opinions are shifting from using platelets solely for haemostasis / wound healing to considering the major contribution platelets have in numerous regulatory processes across different tissues. Platelets have an intriguing ability to store, produce and release distinct subsets of bioactive molecules, including intercellular signalling molecules and neurotransmitters, as well as orchestrating healthy brain function in a tissue-independent role. An awareness of the therapeutic potential of healthy platelets and the proteins which they release is growing. Hence, ensuring that these tasks are replicated in cultured platelets are an enormously arduous task and some newer strategies are discussed in the report by Laura Gutiérrez.

This bimonthly What's Happening section in 2020 provides a short concise summary of the advances being made in the development of cultured blood products, which I hope, will be of interest to TRASCI readers. The success of this bimonthly section in our international journal is due to the collective effort of dedicated colleagues who have answered the call to help. We continue to add new contributors to this section and are open to sharing material of educational value with our readers. This highlights our collective experience, which is more evident during the global COVID-19 pandemic, that we are "stronger together".
